Tralokinumab treatment in patients with moderate-to-severe atopic dermatitis (AD) does not increase Covid-19 severity or interfere with Covid-19 vaccinations, according to a new study.
New study shows digital intervention may increase treatment adherence in AD patients
A digitally delivered intervention showed significant improvements in treatment adherence and other clinical outcomes in atopic dermatitis (AD) patients, according to a new study.
Researchers identify immune biomarker that may predict development of pediatric AD
New research has identified an immune biomarker in newborns that may predict the onset and severity of pediatric atopic dermatitis (AD).
New study highlights significant QoL impairment in patients with photoaggravated AD
According to a recent study, photoaggravated atopic dermatitis (PAD) severely impacts quality of life for patients.
Childhood AD may be linked to parental AD, asthma
According to a recent study, children are more likely to have atopic dermatitis (AD) in the first two years of life if their parents have AD or asthma.
Study shows dietary changes can improve AD symptoms
According to a new study, dietary changes may improve symptoms in patients with mild or moderate atopic dermatitis (AD) when used in conjunction with regular treatment. However, the authors note there are risks associated with elimination diets that should be discussed.
Vitamin D supplementation during pregnancy may lower risk of AD in infants, study shows
According to a new study, taking vitamin D supplements during pregnancy may reduce the likelihood of infants developing atopic dermatitis (AD) in their first year of life.
Study suggests prevalence of keratosis pilaris is low in AD patients
According to a new study, the prevalence of keratosis pilaris (KP) is low in patients with atopic dermatitis (AD).
Depressive symptoms linked to AD severity
According to a new study, depressive symptoms are closely linked to atopic dermatitis (AD) severity and can fluctuate alongside AD severity.
Dupilumab study shows safety and efficacy for up to four years in AD patients
According to a new study, dupilumab shows safety and efficacy for up to four years in treatment of moderate-to-severe atopic dermatitis (AD) in adults.
